mCRPC2014 TRA EVOLUZIONE E RIVOLUZIONE: COME …€¦ · Stomatitis 1 ‐‐ Neuropathy‐motor 1...
Transcript of mCRPC2014 TRA EVOLUZIONE E RIVOLUZIONE: COME …€¦ · Stomatitis 1 ‐‐ Neuropathy‐motor 1...
Marcello Tucci
SCDU Oncologia MedicaAzienda Ospedaliero Universitaria San Luigi di Orbassano
Università degli studi di Torino
mCRPC 2014 TRA EVOLUZIONE E RIVOLUZIONE:COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE
IL CARCINOMA PROSTATICO,UNA MALATTIA ETEROGENEA?
RAZIONALE E RISULTATI DEL TRATTAMENTO CHEMIOTERAPICO ASSOCIATO ALL’ANDROGENO-DEPRIVAZIONE
Tombal. B. Eur J Cancer 2011;47:S179‐188ADT: Androgen Deprivation Therapy; AR: androgen receptor; mets: metastases
The CHAARTED hypothesis
Sweeney C et al. J Clin Oncol 2014;32(June 20 suppl):abstract LBA2ADT: Androgen Deprivation Therapy; AR: androgen receptor
AR independent clones
ADT + Docetaxel
ADT
AR independent clones AR dependent clones
<br /><br />E3805<br />CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
E3805 – CHAARTED study
Sweeney C et al. J Clin Oncol 2014;32(June 20 suppl):abstract LBA2. ADT: androgen deprivation therapy; Mets: Metastases; PS: Performance Status; SRE: Skeletal Related Events; CAB: Complete Androgen Blockade; docétaxel (75mg/m2 every 21 days)
• Open‐label, multicenter, phase III trial conducted in US• Standard dexamethasone premedication but no daily prednisone
ARM A (n=397)ADT + Docetaxelfor 6 cycles
ARM B (n=393) ADT
Follow for time to progression and overall survival
Chemotherapy at investigator’s discretion at progression
Newly diagnosed M1 PCa
Key stratification
• Extent of mets(High vs low)
• Age(≥70 vs < 70 y)
RANDOMIZE
1. Eisenberg M et al. N Engl J Med 1988;339:1036‐42; 2. Crawford E et al. N Engl J Med 1989;321:419‐24;3. Hussain M et al. N Engl J Med 2013;368:1314‐25; 4. Millikan E et al. J Clin Oncol 2008;26:5936‐42
High volume disease is prognostic in metastatic hormone sensitive prostate cancer
Study endpoints• Primary endpoint:
– Overall survival
• Secondary endpoints:– Rate of PSA < 0.2 ng/mL at 6 months and 12 months– Time to biochemical, radiographic or symptomatic progressive disease (PD)
– Time to radiographic or symptomatic PD– Define adverse event profile and tolerability– Quality of life (FACT‐P) until 12 months after randomization
Sweeney C et al. J Clin Oncol 2014;32(June 20 suppl):abstract LBA2PSA: Prostate Specific Antigen; PD: Progressive Disease
CHAARTED Key eligibility criteria
• High volume metastatic disease:– visceral metastases and/or – 4 or more bone metastases (with at least 1 beyond pelvis and
vertebral column)
• At study initiation, only patients with high volume disease were to be accrued– Study amendment to allow patients with low volume
to be enrolled, with stratification on disease volume
Sweeney C et al. J Clin Oncol 2014;32(June 20 suppl):abstract LBA2. ADT: androgen deprivation therapy;
Is high volume disease definitionbased on robust data?
Patient characteristics (1)
Sweeney C et al. J Clin Oncol 2014;32(June 20 suppl):abstract LBA2Mets: Metastases; ADT: androgen deprivation therapy; Docetaxel 75mg/m²
ADT + Docetaxel (n=397) ADT alone (n=393)
n % n %Age (year)Median 64 63
Volume of metsLow 134 33.8% 142 36.1%High 263 66.2% 251 63.9%
Gleason Score4‐6 21 5.9% 21 6.1%7 96 26.9% 82 23.9%8‐10 240 67.2% 240 70.0%
PSA (ng/mL) at time of ADT startMedian 56.0 50.5Range 0.4‐8540.1 0.1‐8056.0
Patient characteristics (2)
Sweeney C et al. J Clin Oncol 2014;32(June 20 suppl):abstract LBA2ADT: androgen deprivation therapy; Docetaxel 75mg/m²
ADT + Docetaxel (n=397) ADT alone (n=393)
n % n %
Prior TreatmentNo localized Rx 289 72.8% 286 73.0%Primary radiation 27 6.8% 33 8.4%Prostatectomy 81 20.4% 73 18.6%
Adjuvant ADTYes 21 5.3% 15 3.8%
Median time from start ADT to randomizationMonths (range) 1.1 (0‐3.9) 1.2 (0‐3.9) No ADT prior to randomization 46 12% 45 11%
Primary endpoint: overall survival
Sweeney C et al. J Clin Oncol 2014;32(June 20 suppl):abstract LBA2ADT: androgen deprivation therapy; DOC: docétaxel; OS: overall survival; mths: months
ADT + DOCMedian 57.6 mths
Hazard Ratio 0.61(95% CI 0.47‐0.80) P=0.0003
ADT aloneMedian 44.0 mths
Overall survival
Overall survival by extent of metastaticdisease at start of ADT
Sweeney C et al. J Clin Oncol 2014;32(June 20 suppl):abstract LBA2ADT: androgen deprivation therapy; DOC: docétaxel 75mg/m²
17‐month benefit in median OS (from 32.2 to 49.2 months)for high volume disease
High volume Low volumeHazard Ratio 0.60
(95% CI 0.45‐0.81) P=0.0006
Hazard Ratio 0.63(95% CI 0.34‐1.17) P=0.1398
ADT aloneMedian 32.2 mths
ADT + DOCNot reached
ADT aloneNot reached
ADT + DOCMedian 49.2 mths
Secondary endpoints
ADT + DOC (N=397)
ADT alone (N=393) P‐value HR
(95%CI*)
PSA <0.2 ng/mL at 6 months 27.5% 14.0% <0.0001
PSA <0.2 ng/mL at 12 months 22.7% 11.7% <0.0001
Median time to CRPC (months)biochemical, symptoms, or radiographic
20.7 14.7 <0.0001 0.56 (0.44, 0.70)
Median time to clinical progression (months)symptoms or radiographic
32.7 19.8 <0.0001 0.49 (0.37, 0.65)
Sweeney C et al. J Clin Oncol 2014;32(June 20 suppl):abstract LBA2ADT: androgen deprivation therapy; DOC: Docetaxel 75mg/m2
Non‐hematologic adverse events (%)
ADT + Docetaxel (N=397)Grade 3 4 5Allergic reaction 2 <1 ‐
Fatigue 4 ‐ ‐
Colitis/Diarrhea 1 ‐ ‐
Stomatitis 1 ‐ ‐
Neuropathy‐motor 1 ‐ ‐
Neuropathy‐sensory 1 ‐ ‐
Thrombo‐embolism <1 1 ‐
Sudden death ‐ ‐ 1 patient
Sweeney C et al. J Clin Oncol 2014;32(June 20 suppl):abstract LBA2ADT: androgen deprivation therapy; Docetaxel 75mg/m2
Safety collected only in the chemotherapy arm
Hematologic adverse events (%)
ADT + Docetaxel (n=397)
Grade 3 4 5
Anemia 1 <1 ‐
Thrombocytopenia ‐ <1 ‐
Neutropenia 3 9 ‐
Febrile neutropenia 4 2 ‐Infection with neutropenia 1 1 ‐Worst grade hem. and non‐hem. toxicity per patient 16% 12% 1 patient
Sweeney C et al. J Clin Oncol 2014;32(June 20 suppl):abstract LBA2ADT: androgen deprivation therapy; Docetaxel 75mg/m2; hem=hematological
Safety collected only in the chemotherapy arm
GETUG 15 results: PFS and OS
):abstract LBA2
Gravis G et al. Lancet Oncol 2013;2:149‐58
0
10
20
30
40
50
60
70
80
90
100
0 12 24 36 48 60Time since randomisation (months)
192
193
146
113
92
69
57
46
34
26
16
14
Number at risk
ADT plusDocetaxel
ADT alone
Clin
ical
pro
gres
sion
fre
e su
rviv
al (
%)
Clinical PFS
ADT + D: 23.5 mths
ADT: 15.4 mths
0
10
20
30
40
50
60
70
80
90
100
0 12 24 36 48 60Time since randomisation (months)
192
193
175
171
145
148
97
102
64
60
31
25
Number at risk
ADT plusDocetaxel
ADT alone
Ove
rall
surv
ival
(%
)
OS
ADT + D: 58.9 mths
ADT: 54.2 mths
ADT plus Docetaxel ADT alone
N pts: 385
GETUG 15 study
):abstract LBA2
Gravis G et al. Lancet Oncol 2013;2:149‐58; Sweeney C et al. J Clin Oncol 2014;32(June 20 suppl ):abstract LBA2
GETUG 15: Study underpowered?
Glass classification defined 21.5% of patients as high risk
How many of these patients could be considered “high risk” according to CHAARTED high risk definition?
OS in ADT arm in GETUG 15 much longer than in CHAARTED(58.9 vs 32.2 months)
Better prognosis
Docetaxel prescribed mainly at PSA progression vs clinical/radiological progression in CHAARTED
May have contributed to a better overall survival
NO DIRECT COMPARISON POSSIBLE
GETUG 15 vs CHAARTED:why this difference in outcomes?
Gravis G et al. Lancet Oncol 2013;2:149-58; Sweeney C et al. ESMO 2014 Meeting Abstract 7560
The near future
Long term overall survival in GETUG 15
STAMPEDE trial
Adding 6 cycles of docetaxel to ADT significantly improves OS in patients with metastatic hormone sensitive prostate cancer
Combination of docetaxel + ADT upfront should be proposed to fit patients with hormone sensitive and high volume metastatic disease
Longer follow‐up is required for men with low volume metastatic disease data from both CHAARTED and GETUG 15 trials
Conclusions